CTOs on the Move

DarioHealth Corporation

www.dariohealth.com

 
DarioHealth Corp. (NASDAQ:DRIO) is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Making the right thing to do the easy ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.dariohealth.com
  • 200 Independence Avenue, S.W.
    Washington, DC USA 20201
  • Phone: 833.914.3796

Executives

Name Title Contact Details

Similar Companies

my event connection

my event connection is a Merrick, NY-based company in the Consumer Services sector.

Avalon Salon Spa

Avalon Salon Spa is a Fredericton, NB-based company in the Consumer Services sector.

DJS and Associates Inc

DJS and Associates Inc is a Lansing, IL-based company in the Consumer Services sector.

trusted business information

trusted business information is a Austin, TX-based company in the Consumer Services sector.

Envy Medical

Envy Medical is one of the most exciting medical technology companies to emerge in the field of dermatology and medical aesthetics. Founded by Ken Karasiuk, the Company flourished on the 2002 patented invention of Dermalinfusiom, method of non-invasive skin therapy, under the SilkPeel™ brand of medical devices. SilkPeel is already a gold standard for leading dermatologists and cosmetic surgeons for treating acne, hyperpigmentation, photo-damage, fine line wrinkles and minor scaring on the face and body.    The Company also owns exclusive rights to a class of novel peptides that show clinical efficacy in the topical treatment of dermatologic indications. The lead peptide, decapeptide-12 was developed by Dr. Basil Hantash`s team of dermatological researchers out of Stanford University, this ground-breaking technology encompasses the only peptide class clinically shown to significantly brighten skin, and address hyperpigmentation. In 2010, the company introduced its first product line for skin brightening under the brand name Lumixyl™. Recent studies show that Lumixyl™, provides comparable or better results than prescription hydroquinone products, and yet is completely non-cytotoxic and therefore does not result in the side effects associated with such prescription level products.